Maintenance or Emergence of Chronic Phase Secondary Cytotoxic T Lymphocyte Responses after Loss of Acute Phase Immunodominant Responses Does Not Protect SIV-Infected Rhesus Macaques from Disease Progression
Table 1
MHC class I allele and CTL Epitope Summary.
Animal Number
Vaccination, Disease Progression
Mamu alleles
CTL Epitope
Significant Trend in CTL Response
Emergence of viral mutants
Restricting Allele for CTL Epitope
16037
LAV, LTNP
, , ,
Gag CTPYDINQ
Increasing
No
01
07, 09
Tat STPESANL
Increasing
No
01
16041
LAV, LTNP
01, , B alleles not
Gag CTPYDINQ
Increasing
Unknown
01
determined
Tat STPESANL
Decreasing
Unknown
01
14757
None, LTNP
, , 23 V,
Gag CTPYDINQ
Increasing
No
01
07, 08
Nef RRLTARGLL
Increasing
No
08
Tat STPESANL
Increasing
Yes
01
Gag TAPSSGRGGNY
Increasing
No
Unknown
16044
LAV, SP
04 V, 23, 3002 V,
Vif YFPCFTAGEV *P
Decreasing
Yes
Unknown
09 V, 21, 49
Gag EQIQWMYRQ
Decreasing
No
Unknown
Gag MYNPTNILDV
Increasing
No
Unknown
16040
LAV, NP (118 W)
01, 23 V, 63N
Gag CTPYDINQ
Decreasing
Yes
01
12416
None, NP (52 W)
04, 25 , 67
Nef RTMSYKLAID
Increasing
Yes
Unknown
11896
None, RP (12 W)
ND
ND
ND
ND
ND
12900
None, RP (16 W)
02, 02 V, 04, 05 V, 07
ND
ND
ND
ND
LAV: live-attenuated vaccine, LTNP: long-term non progressor, SP: slow prog., NP: normal prog., RP: rapid prog., (time of euthanasia in weeks post-challenge). alleles have been reported as protective. (less than 5 amino acid changes in α1 and α2 domains from published sequence of allele listed). (more than 5 amino acid differences in α1 and α2 domains from published sequence of allele listed). utative Epitope, mmunodominant Epitope.